That last paragraph really sums it up. Missling knows AD isn't getting approved and is praying for Rett approval to soften the blow to shareholders. If Rett misses which is then followed by AD having to do another 3-5 year trial, this stock is done.
Considering the approval of trofinetide, I'm optimistic on our near-term Rett prospects.
Your observation about Missling always taking the best case scenario is accurate, but that is pretty typical for young biotechs. Of course, it does mislead some, which is unfortunate. But those folks have bigger problems.
"If Missling feels that AD has the goods to submit an AA, then he should go ahead and do so"
Yes, your quote does give emphasis to what Missling has probably decided NOT to do...sadly I have to admit that I will probably have to accept that after the Excellence Trial result...the bigger potential will (AD) come too many years down the road.....I have to think that's about all I can envision!
News 
Market Data 
Discover 
